Abstract: The present invention relates a retard formulation for oral administration together with a meal comprising at least one active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipient(s) as well as an amount of an agent being able to form a gas (hereinafter also referred to as gas forming agent or gas former), which gas forming agent achieves a homogeneous mixture of the active pharmaceutical ingredient, hereinafter referred to as API, with the content of the stomach, hence providing a continuous initial absorption phase of the API.

Abstract: A lyophilisate having as an active ingredient flupirtine in base form or as a physiologically tolerated salt is suitable for producing a pharmaceutical composition for parenteral administration. The physiologically tolerated salt is an acid addition salt of flupirtine. The lyophilisate contains at least one additive selected from the group consisting of a cake-forming agent, an antioxidant, and a detergent. In a process for producing a flupirtine-containing pharmaceutical composition for parenteral administration, a flupirtine-containing lyophilisate is dissolved in at least one solvent that is an aqueous medium or an organic solvent or a combination thereof to obtain a liquid pharmaceutical composition ready for use. In a process for producing a flupirtine-containing lyophilisate, a flupirtine solution is prepared by dissolving flupirtine base in an aqueous medium and the flupirtine solution is freeze dried.